BiotechTube

mRNA-1653

Phase 1Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Metapneumovirus and Human Parainfluenza Infection

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Trial Timeline

Nov 4, 2019 → Dec 20, 2022

NCT ID
NCT04144348

About mRNA-1653

mRNA-1653 is a phase 1 stage product being developed by Moderna for Human Metapneumovirus and Human Parainfluenza Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04144348. Target conditions include Human Metapneumovirus and Human Parainfluenza Infection.

What happened to similar drugs?

14 of 20 similar drugs in Human Metapneumovirus and Human Parainfluenza Infection were approved

Approved (14) Terminated (4) Active (6)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved

Clinical Trials (2)

NCT IDPhaseStatus
NCT04144348Phase 1Completed
NCT03392389Phase 1Completed

Competing Products

20 competing products in Human Metapneumovirus and Human Parainfluenza Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1653ModernaPhase 1
0
mRNA-1345ModernaPhase 1
0
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
40